| Name | Title | Contact Details |
|---|
San Diego-based Biocept, Inc. (Nasdaq: BIOC) develops and performs diagnostic assays that provide clinically actionable information to improve outcomes for patients with a variety of cancers. Biocept`s unique combination of cell-based and cell-free DNA analysis allows us to rapidly detect and monitor certain cancer biomarkers in blood and cerebrospinal fluid (CSF). Our patented Target Selector™ technology quantitatively analyzes tumor cells for tumor-associated biomarkers, offering high sensitivity and specificity compared with methods currently used by other laboratories. In addition to our broad portfolio of blood-based liquid biopsy tests, we offer the CNSide™ CSF assay, which addresses an unmet clinical need for patients with cancer that has metastasized to the central nervous system. Between 10% and 30% of patients with cancer will develop brain or spinal cord metastasis. Survival is often low, and few are diagnosed early enough for effective therapeutic intervention. CNSide answers three key questions: Is there a tumor? Is there a target for treatment? Is there a trend in treatment response? We offer diagnostic laboratory services for oncologists, pathologists, hospitals, cancer centers, universities, pharmaceutical and clinical researchers, and other healthcare providers. Our CLIA-certified and CAP-accredited laboratory combines a highly trained professional staff with innovative instrumentation for optimal test results and quality control. Biocept works with strategic industry leaders, as well as major cancer centers across the U.S., to further its mission of helping to improve outcomes for cancer patients. We also are utilizing our molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts. Revenue from COVID-19 testing has supported further investment in our core oncology business, positioning the company for long-term success.
Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of spatial biology. The platform features the company`s proprietary, highly multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a fully automated workflow that preserves the sample tissue. The Molecular Cartography technology offers unparalleled sensitivity and specificity that helps scientists detect individual transcripts and rare signals to interpret fundamental biology and rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, and infectious disease. The technology has been under development since 2016 and is currently available through Resolve Biosciences` commercial service laboratory. Resolve Biosciences is privately held and based in Monheim am Rhein, Germany, with a North American facility and laboratory in San Jose, Calif.
Radford Surveys Consulting is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Thomson Research Associates is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Phyto-Microbiome Company Biological Optimizers for Soil, Seed and Plant Vigor Inocucor is an agri-tech company that develops powerful natural biological products for agriculture targeting the phyto-microbiome—the seeds, plants, root systems and the soil surrounding them. Inocucor`s first-generation product, Garden Solution®, soon to be re-branded as Synergro, employs live microbes to actively improve the health of the entire phyto-microbiome. Its second product, Synergro Free and future generations of Inocucor products are powerful biological formulations for bio-stimulation, bio-fertility and bio-control targeting mainstream production agriculture.